IMUNON to Announce Phase 2 OVATION 2 Study Results for IMNN-001 in Advanced Ovarian Cancer Tomorrow

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, is set to reveal significant results from its Phase 2 OVATION 2 Study involving IMNN-001 for advanced ovarian cancer treatment. The announcement will be made on July 30 at 8:00 a.m. Eastern time, followed by an investor conference call at 8:30 a.m. Eastern time to discuss the findings and address any questions. IMNN-001, an interleukin-12 (IL-12) immunotherapy, leverages IMUNON's proprietary TheraPlas™ technology.

IMUNON specializes in developing innovative treatments that harness the body's natural mechanisms to produce safe, effective, and durable responses against a variety of human diseases. The company focuses on advancing its non-viral DNA technology through two primary modalities: TheraPlas® and PlaCCine®. TheraPlas® is designed to encode cytokines and other therapeutic proteins for treating solid tumors using immunological approaches. PlaCCine® aims to deliver DNA-coded viral antigens that trigger robust immune responses.

The lead clinical program, IMNN-001, targets advanced ovarian cancer and is currently in Phase 2 development. This DNA-based immunotherapy prompts the body to produce high levels of potent cancer-fighting molecules, including interleukin-12 and interferon gamma, directly at the tumor site. Additionally, IMUNON has initiated a first-in-human study for its COVID-19 booster vaccine, IMNN-101. The company plans to continue leveraging these modalities and pushing the boundaries of plasmid DNA technology to better address challenging medical conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!